Literature DB >> 12068359

[Moyamoya and Down syndrome: study conducted by meta-analysis].

Paulo Alves Junqueira1, Maria Valeriana L de Moura-Ribeiro.   

Abstract

We present a clinic-epidemiological study of two patients and meta-analysis (period 1977-2000 ) of the co-morbidity of the Down syndrome (DS) and moyamoya syndrome (MMS). Among the 42 patients listed in this survey, meta-analysis permitted to find the highest number of publications by researchers from Japan and United States, followed by Brazil and Italy; prevalence of cerebrovascular disease in suckling and pre school children; first symptomatology was hemiparesis (78.6%), speech disorders (26.2%); ischemic infarction (76.2%); recurring ischemic episodes (62%); bilateral impairment (83.3%). This analysis led to the conclusion that in the clinic-neurological investigation of DS patients with acute hemiparesis episodes, MMS should be included as the most probable diagnosis.

Entities:  

Mesh:

Year:  2002        PMID: 12068359

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  2 in total

1.  Brentuximab-vedotin maintenance following chemotherapy without irradiation for primary intracranial embryonal carcinoma in down syndrome.

Authors:  Mohammad H Abu Arja; Suzanne E Conley; Violeta Salceda; Fahd Al-Sufiani; Daniel R Boué; Jonathan L Finlay
Journal:  Childs Nerv Syst       Date:  2017-12-13       Impact factor: 1.475

Review 2.  A Better Understanding of Moyamoya in Trisomy 21: A Systematic Review.

Authors:  Arowa Abdelgadir; Hamna Akram; Maurice H Dick; Nabeel R Ahmed; Abanti Chatterjee; Sushil Pokhrel; Vaishnavi Vaijaya Kulkarni; Safeera Khan
Journal:  Cureus       Date:  2022-03-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.